文献库，生知库 | 链接生命科学的每一步

Madan, Arvind; Yalavarthy, Rajesh; Kim, Dong Ki; Moon, Ju-Young; Park, Inwhee; Mandayam, Sreedhar; Cortazar, Frank; Kim, Sung Gyun; Enstrom, Amanda; Thomas, Heather; Li, Jiahua; Peng, Stanford L; Chen, Yih-Chieh; Sanders, Jason; Egbuna, Ogo; Tumlin, James

IgA

发表日期：2026

文献求助收藏

Povetacicept (ALPN-303; TACI vTD-Fc), an enhanced, potent dual inhibitor of BAFF and APRIL, ameliorates experimental autoimmune myasthenia gravis in C57BL/6N mice

Povetacicept（ALPN-303；TACI vTD-Fc）是一种增强型强效的BAFF和APRIL双重抑制剂，可改善C57BL/6N小鼠的实验性自身免疫性重症肌无力。

期刊:Frontiers in Immunology

影响因子:5.9

doi:10.3389/fimmu.2025.1533093

Rinaldi, Elena; Puleo, Elisa; Consonni, Alessandra; Miglietti, Martina; Mantegazza, Renato; Wang, NingXin; Peng, Stanford L; Lewis, Katherine E; Dillon, Stacey R; Baggi, Fulvio

Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2)

达沃西替普（ALPN-202）是一种 PD-L1 依赖性 CD28 共刺激剂和双重 PD-L1/CTLA-4 抑制剂，其作为单药疗法以及与帕博利珠单抗联合疗法治疗晚期实体瘤的 I 期研究（NEON-1 和 NEON-2）

期刊:Journal for ImmunoTherapy of Cancer

影响因子:10.6

doi:10.1136/jitc-2024-009474

Davar, Diwakar; Cavalcante, Ludimila; Lakhani, Nehal; Moser, Justin; Millward, Michael; McKean, Meredith; Voskoboynik, Mark; Sanborn, Rachel E; Grewal, Jaspreet S; Narayan, Ajita; Patnaik, Amita; Gainor, Justin F; Sznol, Mario; Enstrom, Amanda; Blanchfield, Lori; LeBlanc, Heidi; Thomas, Heather; Chisamore, Michael J; Peng, Stanford L; Naumovski, Allison

Case report of fatal immune-mediated myocarditis following treatment with davoceticept (ALPN-202), a PD-L1-dependent CD28 costimulator and dual PD-L1/CTLA-4 checkpoint inhibitor, in combination with pembrolizumab

本文报告了一例使用达沃西替普（ALPN-202，一种PD-L1依赖性CD28共刺激分子和双重PD-L1/CTLA-4检查点抑制剂）联合帕博利珠单抗治疗后发生致命性免疫介导性心肌炎的病例。

期刊:Journal for ImmunoTherapy of Cancer

影响因子:10.6

doi:10.1136/jitc-2024-009475

Cavalcante, Ludimila; Chandana, Sreenivasa; Lakhani, Nehal; Enstrom, Amanda; LeBlanc, Heidi; Schmalz, Joseph; Lengyel, Krisztina; Schneider, Frank; Thomas, Heather; Chisamore, Michael J; Peng, Stanford L; Naumovski, Allison; Davar, Diwakar

ICOSL(+) plasmacytoid dendritic cells as inducer of graft-versus-host disease, responsive to a dual ICOS/CD28 antagonist

ICOSL(+)浆细胞样树突状细胞作为移植物抗宿主病的诱导因子，对双重ICOS/CD28拮抗剂有反应

期刊:Science Translational Medicine

影响因子:14.6

doi:10.1126/scitranslmed.aay4799

Adom, Djamilatou; Dillon, Stacey R; Yang, Jinfeng; Liu, Hao; Ramadan, Abdulraouf; Kushekhar, Kushi; Hund, Samantha; Albright, Amanda; Kirksey, Maykala; Adeniyan, Titilayo; Lewis, Katherine E; Evans, Lawrence; Wu, Rebecca; Levin, Steven D; Mudri, Sherri; Yang, Jing; Rickel, Erika; Seaberg, Michelle; Henderson, Katherine; Gudgeon, Chelsea J; Wolfson, Martin F; Swanson, Ryan M; Swiderek, Kristine M; Peng, Stanford L; Hippen, Keli L; Blazar, Bruce R; Paczesny, Sophie

Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study

罗瓦匹妥珠单抗（Rovalpituzumab tesirine，一种靶向DLL3的抗体药物偶联物）治疗复发性小细胞肺癌：一项首次人体试验、同类首创、开放标签的1期研究

期刊:Lancet Oncology

影响因子:35.9

doi:10.1016/S1470-2045(16)30565-4

Rudin, Charles M; Pietanza, M Catherine; Bauer, Todd M; Ready, Neal; Morgensztern, Daniel; Glisson, Bonnie S; Byers, Lauren A; Johnson, Melissa L; Burris, Howard A 3rd; Robert, Francisco; Han, Tae H; Bheddah, Sheila; Theiss, Noah; Watson, Sky; Mathur, Deepan; Vennapusa, Bharathi; Zayed, Hany; Lally, Satwant; Strickland, Donald K; Govindan, Ramaswamy; Dylla, Scott J; Peng, Stanford L; Spigel, David R

Dose-escalation of human anti-interferon-α receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study

在系统性硬化症患者中，人抗干扰素-α受体单克隆抗体MEDI-546的剂量递增研究：一项1期、多中心、开放标签研究

期刊:Arthritis Research & Therapy

影响因子:4.6

doi:10.1186/ar4492

Goldberg, Avram; Geppert, Thomas; Schiopu, Elena; Frech, Tracy; Hsu, Vivien; Simms, Robert W; Peng, Stanford L; Yao, Yihong; Elgeioushi, Nairouz; Chang, Linda; Wang, Bing; Yoo, Stephen

Foxo1 regulates marginal zone B-cell development.

Foxo1 调控边缘区 B 细胞发育

期刊:European Journal of Immunology

影响因子:3.7

doi:10.1002/eji.200939817

Chen Jing, Limon Jose J, Blanc Caroline, Peng Stanford L, Fruman David A

细胞生物学

发表日期：2010

文献求助收藏

Forkhead transcription factors in chronic inflammation

慢性炎症中的叉头转录因子

期刊:International Journal of Biochemistry & Cell Biology

影响因子:2.8

doi:10.1016/j.biocel.2009.10.013

Active inhibition of plasma cell development in resting B cells by microphthalmia-associated transcription factor

小眼畸形相关转录因子主动抑制静息B细胞中浆细胞的发育

期刊:Journal of Experimental Medicine

影响因子:10.6

doi:10.1084/jem.20040612

Lin, Ling; Gerth, Andrea J; Peng, Stanford L

Povetacicept for IgA Nephropathy and Primary Membranous Nephropathy

Povetacicept 用于治疗 IgA 肾病和原发性膜性肾病

Povetacicept (ALPN-303; TACI vTD-Fc), an enhanced, potent dual inhibitor of BAFF and APRIL, ameliorates experimental autoimmune myasthenia gravis in C57BL/6N mice

Povetacicept（ALPN-303；TACI vTD-Fc）是一种增强型强效的BAFF和APRIL双重抑制剂，可改善C57BL/6N小鼠的实验性自身免疫性重症肌无力。

Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2)

达沃西替普（ALPN-202）是一种 PD-L1 依赖性 CD28 共刺激剂和双重 PD-L1/CTLA-4 抑制剂，其作为单药疗法以及与帕博利珠单抗联合疗法治疗晚期实体瘤的 I 期研究（NEON-1 和 NEON-2）

Case report of fatal immune-mediated myocarditis following treatment with davoceticept (ALPN-202), a PD-L1-dependent CD28 costimulator and dual PD-L1/CTLA-4 checkpoint inhibitor, in combination with pembrolizumab

本文报告了一例使用达沃西替普（ALPN-202，一种PD-L1依赖性CD28共刺激分子和双重PD-L1/CTLA-4检查点抑制剂）联合帕博利珠单抗治疗后发生致命性免疫介导性心肌炎的病例。

ICOSL(+) plasmacytoid dendritic cells as inducer of graft-versus-host disease, responsive to a dual ICOS/CD28 antagonist

ICOSL(+)浆细胞样树突状细胞作为移植物抗宿主病的诱导因子，对双重ICOS/CD28拮抗剂有反应

Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study

罗瓦匹妥珠单抗（Rovalpituzumab tesirine，一种靶向DLL3的抗体药物偶联物）治疗复发性小细胞肺癌：一项首次人体试验、同类首创、开放标签的1期研究

Dose-escalation of human anti-interferon-α receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study

在系统性硬化症患者中，人抗干扰素-α受体单克隆抗体MEDI-546的剂量递增研究：一项1期、多中心、开放标签研究

Foxo1 regulates marginal zone B-cell development.

Foxo1 调控边缘区 B 细胞发育

Forkhead transcription factors in chronic inflammation

慢性炎症中的叉头转录因子

Active inhibition of plasma cell development in resting B cells by microphthalmia-associated transcription factor

小眼畸形相关转录因子主动抑制静息B细胞中浆细胞的发育